







Robust Pipeline of Switch-Control Kinase Inhibitors

		PRE-CLINICAL	PHASE 1	PHASE 1B/2	PHASE 3	REGULATORY SUBMISSION	APPROVED	COMMERCIAL RIGHTS	
QINLOCK (ripretinib) 50mg tablets Broad-Spectrum Inhibitor of KIT and PDGFRA	GIST ≥4 th Line (INVICTUS Study)						 (1)	     (2) (2)	
	GIST 2 nd Line (INTRIGUE Study)								deciphera (2)
	GIST Post-Imatinib in Combination with Binimetinib								
Vimseltinib (DCC-3014) Selective Inhibitor of CSF1R	Tenosynovial Giant Cell Tumor (TGCT)								deciphera
Rebastinib Selective Inhibitor of TIE2	Multiple Solid Tumors in Combination with Paclitaxel								deciphera
	Multiple Solid Tumors in Combination with Carboplatin								deciphera
DCC-3116 Selective Inhibitor of ULK	RAS/RAF Mutant Cancers in Combination with Trametinib							deciphera	
Additional Programs	Undisclosed							deciphera	



Notes: CSF1R=colony-stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFRA=platelet-derived growth factor receptor α; RAS=rat sarcoma gene; TIE2=TEK tyrosine kinase; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like kinase; (1) Submitted and received validation of a Marketing Authorisation Application for QINLOCK in 4th line GIST by the European Medicines Agency; (2) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK.